Clinical Trials Logo

Filter by:
NCT ID: NCT05244304 Active, not recruiting - Stargardt Disease 1 Clinical Trials

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease

DRAGON
Start date: March 28, 2022
Phase: Phase 3
Study type: Interventional

The primary objective of this trial is to assesses the efficacy of tinlarebant in slowing the rate of growth of atrophic lesion(s) in adolescent subjects with STGD1

NCT ID: NCT05225935 Active, not recruiting - Clinical trials for Ventricular Tachycardia

Computed Tomography-Guided Catheter Ablation for Ventricular Tachycardia

InEurHeart
Start date: June 29, 2022
Phase: N/A
Study type: Interventional

This double arm randomized study will compare 2 ventricular tachycardia ablation strategies: the standard strategy based on invasive substrate and VT mapping with 3D electro-anatomical system vs a tailored strategy which identifies targets based on pre-procedural CT-scan imaging. The primary endpoint will be procedure duration and secondary endpoints will include safety and efficacy criteria as well as medico-economic evaluation.

NCT ID: NCT05174507 Active, not recruiting - Clinical trials for Postprandial Hypoglycemia

Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes

Hypo-PrEA
Start date: June 24, 2022
Phase: Phase 2
Study type: Interventional

This study is to analyze whether the SGLT2-inhibitor empagliflozin or the IL-1 receptor antagonist anakinra may improve postprandial hypoglycemia in subjects with prediabetes.

NCT ID: NCT05163288 Active, not recruiting - Clinical trials for Niemann-Pick Disease, Type C

A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C

Start date: June 30, 2022
Phase: Phase 3
Study type: Interventional

A pivotal, randomized, double-blind, placebo controlled, multi-center therapeutic study for patients age 4 and older with a confirmed diagnosis of Niemann Pick disease type C (NPC). The objective of this study is to evaluate the safety, tolerability and efficacy of N-acetyl-L-leucine (IB1001) compared to standard of care.

NCT ID: NCT05146700 Active, not recruiting - Trauma Clinical Trials

Restrictive vs. Liberal Oxygen in Trauma

TRAUMOX2
Start date: December 10, 2021
Phase: Phase 4
Study type: Interventional

Victims of trauma are often healthy individuals prior to the incident, but acquire numerous complications including sepsis and pulmonary complications and diminished quality of life after trauma. According to Advanced Trauma Life Support guidelines, all severely injured trauma patients should receive supplemental oxygen. The objective of TRAUMOX2 is to compare the effect of a restrictive versus liberal oxygen strategy the first eight hours following trauma on the incidence of 30-day mortality and/or major respiratory complications (pneumonia and acute respiratory distress syndrome) within 30 days (combined primary endpoint).

NCT ID: NCT05144256 Active, not recruiting - Clinical trials for Pediatric Pyruvate Kinase Deficiency

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period

ACTIVATE-KidsT
Start date: June 8, 2022
Phase: Phase 3
Study type: Interventional

ACTIVATE-KidsT (AG348-C-022) is a multicenter study designed to evaluate the efficacy and safety of treatment with mitapivat compared with placebo in pediatric participants with pyruvate kinase deficiency (PK deficiency) who are regularly receiving blood transfusions. Participants will be randomized 2:1 to receive either mitapivat or matching placebo. Randomization will be stratified by age (1 to < 6 years, 6 to < 12 years, 12 to < 18 years) and splenectomy status. Participants will be dosed by age and weight during a double-blind period consisting of an 8-week dose titration period followed by a 24-week fixed-dose period. Participants who complete the double-blind period will be eligible to receive mitapivat for up to 5 years in the open-label extension (OLE) period.

NCT ID: NCT05128500 Active, not recruiting - Psoriatic Arthritis Clinical Trials

Follow-up Evaluating Clinical and Radiological Outcomes of Total Shoulder Arthroplasty With Permedica's MIRAI Prosthesis

Start date: July 12, 2019
Phase:
Study type: Observational

This observational study is conducted in order to evaluate the effectiveness of the primary total shoulder arthroplasty with the Permedica's MIRAI Modular Shoulder Prosthesis System on the general population of patients who are about to undergo this surgery for every indication. Patients requiring a revision shoulder arthroplasty will not be enrolled. The effectiveness will be evaluated in terms of recovery of shoulder function and stability of the prosthetic implant. The incidence of complications, adverse and serious adverse events will also be studied. Additional study aim is to evaluate a medium/long term survival of the prosthesis. The duration of the study per single subject is 5 years.

NCT ID: NCT05122988 Active, not recruiting - Clinical trials for Adverse Childhood Experiences

Facing Adverse Childhood Experiences

FACE
Start date: October 28, 2021
Phase:
Study type: Observational

Childhood experiences affect psychosocial well-being and mental health across the life course for better or worse. The aim of the present study is to investigate how adverse childhood experiences before the age of 18 impact psychological functioning in young adulthood, and whether social information processing and emotion regulation may mediate these associations.

NCT ID: NCT05114252 Active, not recruiting - Healthy Clinical Trials

Amblyopia and Stereoptic Games for Vision

AMBER
Start date: December 6, 2022
Phase: N/A
Study type: Interventional

Amblyopia is the most common developmental vision disorder in children, caused by abnormal visual experience in early life, especially a difference in refraction between the eyes, a misalignment of the eye axes, a combination of both. Besides a significant reduced visual acuity, the patients show deficits in 3D vision and functional vision impairment like reduced reading speed, selective attention or motor control skills. The gold standard treatment for amblyopia, occlusion therapy, can lead to relapses or residual amblyopia (i.e., amblyopia that persist into adulthood). The current study aims to test the efficacy of a novel home-based child-friendly rehabilitation program for amblyopia, Vivid Vision Home, involving playing serious videogames on a virtual reality (VR) headset at home. The VR training will be compared to standard care (wearing a spectacle correction) and to age-matched typically developing individuals. A cross-over design will be used so that each participant will receive both treatments (games, spectacles). There is a growing number of studies showing benefits of binocular stimulation for visual acuity and stereovision, but provided mainly by level III studies, with a need for rigorous level I or II studies, using more engaging therapies, to confirm or refute the efficacy of this approach as an adjunct or replacement for current amblyopia treatments. Embedding binocular stimulation in engaging, immersive serious games delivered on VR headsets at home, as implemented by Vivid Vision Home, can address this question.

NCT ID: NCT05079828 Active, not recruiting - Prostate Cancer Clinical Trials

Head-to-head Comparison of 68Ga-PSMA-11 and 18F-PSMA-1007

Start date: July 7, 2022
Phase: N/A
Study type: Interventional

The aim of this study is to provide robust data on the head-to-head comparison of the two ligands of the prostate specific membrane antigen (PSMA) available in Switzerland for positron emission tomography (PET)-imaging, i.e. 68Ga-PSMA-11 und 18F-PSMA-1007.